The collaboration between ELDICO Scientific and Crystal Pharmatech marks a significant advancement in the field of pharmaceutical development, particularly in the Asia-Pacific region. This partnership introduces the ELDICO ED-1 electron diffractometer, the world's first dedicated device for MicroED, a groundbreaking technique in solid-state characterization. By deploying this technology, Crystal Pharmatech becomes a pioneer in Asia, offering a unique service that directly determines crystal structures, chirality, and absolute configuration from sub-micron crystalline powders. This capability is a game-changer, especially for small-molecule compounds, as it enables the identification and understanding of complex polymorphic mixtures and low-crystallinity materials. The ED-1's automated and 24/7 operation further enhances its utility, making it a scalable and high-throughput platform. This development is particularly exciting as it transforms MicroED from a specialized technique into a routine tool for pharmaceutical development, accelerating preformulation, formulation, and CMC development. The collaboration's impact extends beyond the technical aspects, as it addresses a critical need in the industry: the determination of crystal structures for every polymorph. This goal, once a long-standing aspiration in solid-state science, is now becoming more achievable, thanks to the expertise of Crystal Pharmatech and the innovative ED-1 platform. The partnership's success lies in its ability to integrate cutting-edge technology into practical applications, driving the adoption of MicroED across the pharmaceutical, chemical, and materials science industries. This collaboration is a testament to the power of innovation and collaboration in advancing scientific research and industrial practices, particularly in a region where such advancements are crucial for global drug development.
